Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance.

Hashmi AA, Khan EY, Irfan M, Ali R, Asif H, Naeem M, Nisar L, Faridi N, Khan A, Edhi MM.

BMC Res Notes. 2019 Jan 18;12(1):35. doi: 10.1186/s13104-019-4090-x.

2.

The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.

Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, Tanguay S, Kassouf W, Aprikian A, Brimo F.

Hum Pathol. 2014 Mar;45(3):488-97. doi: 10.1016/j.humpath.2013.10.012. Epub 2013 Oct 23. Review.

PMID:
24406017
3.

Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.

Mannan R, Bhasin TS, Manjari M, Singh G, Bhatia PK, Sharma S.

Indian J Pathol Microbiol. 2016 Oct-Dec;59(4):489-495. doi: 10.4103/0377-4929.191794.

4.

PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Morais CL, Herawi M, Toubaji A, Albadine R, Hicks J, Netto GJ, De Marzo AM, Epstein JI, Lotan TL.

Prostate. 2015 Oct;75(14):1610-9. doi: 10.1002/pros.23042. Epub 2015 Jul 14.

5.

Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.

Warrick JI, Humphrey PA.

Am J Surg Pathol. 2013 Nov;37(11):1709-14. doi: 10.1097/PAS.0b013e318293d85b.

PMID:
23797726
6.

Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.

Downes MR, Satturwar S, Trudel D, van der Kwast TH.

Pathol Res Pract. 2017 Jan;213(1):34-38. doi: 10.1016/j.prp.2016.10.007. Epub 2016 Oct 26.

PMID:
27913052
7.

[Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia].

Allina DO, Kekeeva TV, Moskvina LV, Shikeeva AA, Andreeva YY, Zavalishina LE, Frank GA.

Arkh Patol. 2015 Sep-Oct;77(5):36-42. doi: 10.17116/patol201577536-42. Russian.

PMID:
26978019
8.

High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Box A, Alshalalfa M, Hegazy SA, Donnelly B, Bismar TA.

Tumour Biol. 2016 Sep;37(9):12287-12299. Epub 2016 Jun 7.

PMID:
27271990
9.

Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.

Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, Kamata Y, van Leenders GJ, Visakorpi T, Egawa S.

Pathol Int. 2012 Nov;62(11):742-8. doi: 10.1111/pin.12006.

PMID:
23121605
10.

Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma.

Wang CC, De Marzo AM, Lotan TL, Epstein JI.

Hum Pathol. 2015 Apr;46(4):554-7. doi: 10.1016/j.humpath.2014.12.007. Epub 2014 Dec 31.

PMID:
25656929
11.

SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.

Huang KC, Bégin LR, Palanisamy N, Donnelly B, Bismar TA.

Urol Oncol. 2016 May;34(5):235.e1-10. doi: 10.1016/j.urolonc.2015.11.015. Epub 2015 Dec 22.

PMID:
26725250
12.

SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.

Pierconti F, Martini M, Cenci T, Petrone GL, Ricci R, Sacco E, Bassi PF, Larocca LM.

Prostate. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1.

PMID:
28144985
13.

Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.

Kim SH, Kim SH, Joung JY, Lee GK, Hong EK, Kang KM, Yu A, Nam BH, Chung J, Seo HK, Park WS, Lee KH.

PLoS One. 2015 Apr 21;10(4):e0122498. doi: 10.1371/journal.pone.0122498. eCollection 2015.

14.

Micropapillary carcinoma: new variant of prostatic acinar adenocarcinoma.

Mneimneh WS, Linos K, Shah P, Jennings TA, Fisher H, Nazeer T.

Arch Pathol Lab Med. 2012 Nov;136(11):1447-50. doi: 10.5858/arpa.2011-0359-CR.

PMID:
23106591
15.

ERG positive prostatic cancer may show a more angiogenetic phenotype.

Strzępek A, Kaczmarczyk K, Białas M, Szpor J, Dyduch G, Szopiński T, Chłosta P, Okoń K.

Pathol Res Pract. 2014 Dec;210(12):897-900. doi: 10.1016/j.prp.2014.07.009. Epub 2014 Aug 9.

PMID:
25220615
16.

Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.

He H, Osunkoya AO, Carver P, Falzarano S, Klein E, Magi-Galluzzi C, Zhou M.

BJU Int. 2012 Dec;110(11 Pt B):E751-5. doi: 10.1111/j.1464-410X.2012.11557.x. Epub 2012 Oct 9.

17.

TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y.

Tumour Biol. 2016 Sep;37(9):12397-12402. Epub 2016 Jun 20. Erratum in: Tumour Biol. 2016 Oct;37(10 ):14331.

PMID:
27320318
18.

TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.

Lotan TL, Toubaji A, Albadine R, Latour M, Herawi M, Meeker AK, DeMarzo AM, Platz EA, Epstein JI, Netto GJ.

Mod Pathol. 2009 Mar;22(3):359-65. doi: 10.1038/modpathol.2008.236. Epub 2009 Jan 16.

19.

ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.

Schneider TM, Osunkoya AO.

Mod Pathol. 2014 Aug;27(8):1174-8. doi: 10.1038/modpathol.2013.248. Epub 2014 Jan 10.

20.

Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook.

Suryavanshi M, Mehta A, Jaipuria J, Sharma AK, Rawal S, Seth N.

Urol Oncol. 2015 Jul;33(7):331.e9-15. doi: 10.1016/j.urolonc.2015.03.017. Epub 2015 Apr 17.

PMID:
25899828

Supplemental Content

Support Center